We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Madrigal Pharmaceuticals
An SI Board Since April 2018
Posts SubjectMarks Bans Symbol
124 14 0 MDGL
Emcee:  Lynn Type:  Moderated
"Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The company‚Äôs lead candidate, MGL-3196, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist in clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and familial dyslipidemias/hypercholesterolemias, among other related indications. [source:]"

MDGL has been up well over 600% the past year!

Besides discussion and new on MDGL, discussion of other pharmaceudicals working on NASH is welcome. Some of these are VKTX, GLMD, ICPT , GNFTF , GILD, and PFE (for which there is a thread here at SI).
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
124I think that Pinnacle is main (master) CRO, and sites that are controlled by theMiljenko Zuanic-August 7
123We got the regular BS this morning. NCT03900429 still showing only Pinnacle as tuck-August 7
122Today it was @83...suckers....Miljenko Zuanic-July 26
121Friedman want to sell company and he screwed up, so Investors are thirsty for sMiljenko Zuanic-July 22
120I'd prefer your scenario, but I'm not really expecting anything other thtuck-July 22
119I do not like that $70! :-( I hope it may recover after 2Q report, to 120-30 levMiljenko Zuanic-July 22
118Good color regarding exposure, thanks. Technically, breaking down and may see mtuck-July 22
117<about my very poor judgement > on company and managements....and first orMiljenko Zuanic-July 22
116I am concerned about many thinks,.... but most of all about my very poor judgemetuck-July 22
115I am concerned about many thinks,.... but most of all about my very poor judgemeMiljenko Zuanic-July 22
114<5.Biopsy-proven NASH (Baseline liver biopsy) based on a liver biopsy obtaineMiljenko Zuanic-July 20
113I'm a little concerned about the powering for the stage 2/3 cohorts now. Totuck-July 19
112Could be to speed enrollment.DewDiligence_on_SI-July 19
111Two new updates to the P3 clinical trial. One is a name - "MAESTRO-NASH&qutuck-July 19
110<Few details were unveiled about that deal, which concerned two undisclosed tMiljenko Zuanic-July 2
109B-I licenses dual-acting NASH candidate: investorshub.advfn.comDewDiligence_on_SI-July 1
108A competitor with a singular focus on NASH via activation of most - but not all tuck-June 20
107I poked around in the CRO's website. They have two sites in San Antonio andtuck1May 21
106Because of the Pinnacle Clinical Research involvement, we may not know which (hoMiljenko Zuanic-May 21
105Worried? What for? Just enjoy another $60-70/share decline...(just kiding). I reMiljenko Zuanic-May 15
104"An experienced group of NASH investigators and clinical sites around the wtuck-May 14
103I am in Croatia, slow respond. Longer trial is must, surrogate/biopsy (samplingMiljenko Zuanic-May 3
102I don't think I learned anything of consequence from reading those tweets.DewDiligence_on_SI-April 30
101Interesting "tweetorial" from a nephrologist, concerning NASH trial outuck-April 30
100<These big companies seem to have more disasters than successes on buyouts.&gMiljenko Zuanic-April 16
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):